** Shares of drug developer Forte Biosciences FBRX.O rise 132.4% to $13.77
** Company says private placement of its shares, worth $53 mln, oversubscribed
** Funds to support development of company's experimental drug, FB102, to treat autoimmune diseases - FBRX
** Received support from new and existing investors, including OrbiMed, Janus Henderson Investors and Tybourne Capital Management - CEO Paul Wagner
** Despite session's gains, stock down 34.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。